Samus Therapeutics Announces Study Publication in Communications Biology on the Importance of Epichaperome Inhibition for Enhancing the Vulnerability of Cancer Cells

/PRNewswire/ -- Samus Therapeutics, Inc. ("Samus Therapeutics" or the "Company"), a privately held, Boston-based biopharmaceutical company developing...

Related Keywords

Boston ,Massachusetts ,United States ,Barbara Wallner ,Sloan Kettering ,Gabriela Chiosis ,Prnewswire Samus Therapeutics Inc ,Communications Biology ,Member Of The Chemical Biology Program ,Samus Therapeutics Inc ,Chief Scientific Officer ,Chemical Biology Program ,Sloan Kettering Institute ,Memorial Sloan Kettering Cancer ,Memorial Sloan Kettering ,Samus Therapeutics ,Nc ,